Karyopharm Therapeutics Inc. (NASDAQ:KPTI) finished Friday with an addition of $0.05 to close at $1.44, an upside of 3.60 percent. An average of 1,659,240 shares of common stock have been traded in the last five days. There was a fall of -$0.2200 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 1,491,010 shares traded, while the 50-day average volume stands at 3,180,626.
KPTI stock has decreased by -14.79% in the last month. The company shares reached their 1-month lowest point of $1.3550 on 08/25/23. With the stock rallying to its 52-week high on 04/17/23, shares of the company touched a low of $1.37 and a high of $6.01 in 52 weeks. It has reached a new high 13 times so far this year and lost -57.65% or -$1.9600 in price. In spite of this, the price is down -76.04% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
KPTI stock investors should be aware that Karyopharm Therapeutics Inc. (KPTI) stock had its last reported insider trading activity 19 days ago on Aug 07. In this transaction, the insider spent $6,402. EVP, Chief Development Officer, Poulton Stuart, disposed of 2,845 shares at a price of $1.70 on Jul 28. The insider now owns more than $4,836 worth of shares. Prior to that, President and CEO Paulson Richard A. went on to Sale 3,538 shares at $1.72 each on Jul 05. An amount of $6,085 was transacted.
Valuation Metrics
Karyopharm Therapeutics Inc. (KPTI) stock’s beta is 0.01. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.14.
Financial Health
The quick ratio of Karyopharm Therapeutics Inc. for the three months ended June 29 was 4.90, and the current ratio was 4.90, indicating that the company is able to meet its debt obligations. Karyopharm Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -90.14%, while its operating margin for the same period stands at -85.70%. Its gross profit as reported stood at $151.86 million compared to revenue of $157.07 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Karyopharm Therapeutics Inc.’s return on assets was -46.70%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$32.63 million in the quarter, while revenues of -$34.13 million were shrunk -50.35%. The analyst consensus anticipated Karyopharm Therapeutics Inc.’s latest quarter earnings to come in at -$0.34 per share, but it turned out to be -$0.29, a 14.70% surprise. For the quarter, EBITDA amounted to -$30.31 million. Shareholders own equity worth $114.36 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Karyopharm Therapeutics Inc. (KPTI) price momentum. RSI 9-day as of the close on 25 August was 31.02%, suggesting the stock is Neutral, with historical volatility in this time frame at 50.95%.
As of today, KPTI’s price is $1.4680 -13.25% or -$0.2200 from its 5-day moving average. KPTI is currently trading -20.00% lower than its 20-day SMA and -63.73% lower than its 100-day SMA. However, the stock’s current price level is -31.10% below the SMA50 and -72.04% below the SMA200.
The stochastic %K and %D were 7.76% and 4.47%, respectively, and the average true range (ATR) was 0.1234. With the 14-day stochastic at 16.83% and the average true range at 0.1261, the RSI (14) stands at 34.34%. The stock has reached -0.1400 on the 9-day MACD Oscillator while the 14-day reading was at -0.1764.
Analyst Ratings
Piper Sandler launched coverage on Karyopharm Therapeutics Inc. (NASDAQ: KPTI) in its analyst report released on January 19, 2023. The firm assigned the stock an Overweight rating. The consensus rating for Karyopharm Therapeutics Inc. (KPTI) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell KPTI, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 4 others rate it as a “buy”.
What is KPTI’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $10.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Karyopharm Therapeutics Inc. (KPTI) stock is $6.50.
